Lessons learned from statin trials

被引：11

作者：

Auer, J ^{[1
]}

Berent, R ^{[1
]}

Eber, B ^{[1
]}

机构：

[1] Gen Hosp Wels, Dept Med 2, A-4600 Wels, Austria

来源：

CLINICAL CARDIOLOGY | 2001年 / 24卷 / 04期

关键词：

statins; 3-hydroxy-3-methylglutaryl coenzyme-A-reductase; atherosclerosis; coronary artery disease; clinical trials; low-density lipoprotein cholesterol; endothelial function;

D O I：

10.1002/clc.4960240404

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This article aims to review lessons learned about lipid lowering and statins in the past decade and to consider what developments the future may hold. Results from a series of landmark clinical trials confirm that statins significantly reduce cardiovascular morbidity and mortality in patients with and without previous coronary artery disease. The potential of this drug class has yet to be fully explored. Studies currently under way will answer many of the outstanding questions.

引用

页码：277 / 280

页数：4

共 19 条

[1] MEVINOLIN - A HIGHLY POTENT COMPETITIVE INHIBITOR OF HYDROXYMETHYLGLUTARYL-COENZYME-A REDUCTASE AND A CHOLESTEROL-LOWERING AGENT [J].

ALBERTS, AW ;

CHEN, J ;

KURON, G ;

HUNT, V ;

HUFF, J ;

HOFFMAN, C ;

ROTHROCK, J ;

LOPEZ, M ;

JOSHUA, H ;

HARRIS, E ;

PATCHETT, A ;

MONAGHAN, R ;

CURRIE, S ;

STAPLEY, E ;

ALBERSSCHONBERG, G ;

HENSENS, O ;

HIRSHFIELD, J ;

HOOGSTEEN, K ;

LIESCH, J ;

SPRINGER, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (07) :3957-3961

[2] Systematic review on the risk and benefit of different cholesterol-lowering interventions [J].

Bucher, HC ;

Griffith, LE ;

Guyatt, GH .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (02) :187-195

[3] REDUCTION IN CARDIOVASCULAR EVENTS DURING PRAVASTATIN THERAPY - POOLED ANALYSIS OF CLINICAL EVENTS OF THE PRAVASTATIN ATHEROSCLEROSIS INTERVENTION PROGRAM [J].

BYINGTON, RP ;

JUKEMA, JW ;

SALONEN, JT ;

PITT, B ;

BRUSCHKE, AV ;

HOEN, H ;

FURBERG, CD ;

MANCINI, J .

CIRCULATION, 1995, 92 (09) :2419-2425

[4] Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].

Downs, JR ;

Clearfield, M ;

Weis, S ;

Whitney, E ;

Shapiro, DR ;

Beere, PA ;

Langendorfer, A ;

Stein, EA ;

Kruyer, W ;

Gotto, AM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622

[5] Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes -: The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial [J].

Dupuis, J ;

Tardif, JC ;

Cernacek, P ;

Théroux, P .

CIRCULATION, 1999, 99 (25) :3227-3233

[6] Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (lipoprotein and coronary atherosclerosis study [LCAS]) [J].

Herd, JA ;

Ballantyne, CM ;

Farmer, JA ;

Ferguson, JJ ;

Jones, PH ;

West, S ;

Gould, KL ;

Gotto, AM .

AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (03) :278-286

[7]

HOLDAAS H, 1998, 17 WORLD C TRANSPL S

[8] Effect of statins on risk of coronary disease - A meta-analysis of randomized controlled trials [J].

LaRosa, JC ;

He, J ;

Vupputuri, S .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (24) :2340-2346

[9]

Meade T, 1999, EUR HEART J, V20, P725

[10]

PEDERSEN TR, 1994, LANCET, V344, P1383

← 1 2 →